Nykode Therapeutics ASA Logo

Nykode Therapeutics ASA

Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.

NYKD | OL

Overview

Corporate Details

ISIN(s):
NO0010714785
LEI:
254900UKQHWYZJD22017
Country:
Norway
Address:
Gaustadalleen 21, 0349 Oslo
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies and vaccines. The company's core is its innovative, modular technology platform centered on the proprietary Vaccibody™ molecule. This platform is engineered to deliver antigens with tailored hyper-targeting to Antigen Presenting Cells, inducing rapid, robust, and long-lasting immune responses. Nykode's approach demonstrates a positive safety profile and has the potential to treat and prevent a wide range of diseases, with a significant focus on cancer.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 07:00
Regulatory News Service
Nykode Therapeutics Strengthens Intellectual Property Portfolio with New U.S. P…
English 140.5 KB
2025-11-04 07:00
Regulatory News Service
Nykode Therapeutics Strengthens Intellectual Property Portfolio with New U.S. P…
English 5.3 KB
2025-10-14 08:17
Major Shareholding Notification
Disclosure of Large Shareholding - Nykode Therapeutics ASA - Attachment: CGC_21…
English 165.9 KB
2025-10-14 08:17
Major Shareholding Notification
Disclosure of Large Shareholding - Nykode Therapeutics ASA - Attachment: SCWF_2…
English 162.4 KB
2025-10-14 08:17
Major Shareholding Notification
Disclosure of Large Shareholding - Nykode Therapeutics ASA
English 1.0 KB
2025-10-10 17:44
Director's Dealing
Nykode Therapeutics – Grant of Share Options - Attachment: Attachment Options 2…
English 181.6 KB
2025-10-10 17:44
Remuneration Information
Nykode Therapeutics – Grant of Share Options
English 775 bytes
2025-10-10 14:00
Director's Dealing
Nykode Therapeutics - Mandatory notification of acquisition of shares by primar…
English 199.2 KB
2025-10-10 14:00
Major Shareholding Notification
Nykode Therapeutics - Mandatory notification of acquisition of shares by primar…
English 778 bytes
2025-10-10 12:36
Director's Dealing
Nykode Therapeutics - Mandatory notification of acquisition of shares by primar…
English 189.4 KB
2025-10-10 12:36
Director's Dealing
Nykode Therapeutics - Mandatory notification of acquisition of shares by primar…
English 708 bytes
2025-10-09 20:27
Report Publication Announcement
Financial calendar
English 473 bytes
2025-08-27 07:01
Regulatory News Service
Nykode Announces Updated Strategy to Increase Value for Patients and Shareholde…
English 176.0 KB
2025-08-27 07:01
Regulatory News Service
Nykode Announces Updated Strategy to Increase Value for Patients and Shareholde…
English 12.9 KB
2025-08-27 07:00
Interim Report
Nykode Therapeutics - Quarterly report Q2 2025 - Attachment: 250827 Nykode Quar…
English 11.4 MB

Automate Your Workflow. Get a real-time feed of all Nykode Therapeutics ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nykode Therapeutics ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nykode Therapeutics ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America FDMT
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
Abivax S.A. Logo
Biotech developing oral drugs for chronic inflammatory diseases like colitis and Crohn's.
United States of America ABVX
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Absci Corp Logo
A generative AI drug creation platform for designing and optimizing biologic therapeutics.
United States of America ABSI
ABVC BIOPHARMA, INC. Logo
Develops plant-based drugs and medical devices for CNS, oncology, and ophthalmic disorders.
United States of America ABVC

Talk to a Data Expert

Have a question? We'll get back to you promptly.